Israel Englander’s Compass Therapeutics CMPX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.3M Buy
4,713,247
+3,867,027
+457% +$11.4M ﹤0.01% 2248
2026
Q1
$4.48M Sell
846,220
-2,263,066
-73% -$13.1M ﹤0.01% 3080
2025
Q4
$16.7M Sell
3,109,286
-128,286
-4% -$592K 0.01% 1742
2025
Q3
$11.3M Buy
3,237,572
+2,386,367
+280% +$7.54M ﹤0.01% 2277
2025
Q2
$2.21M Buy
851,205
+306,117
+56% +$631K ﹤0.01% 3795
2025
Q1
$1.04M Buy
545,088
+511,231
+1,510% +$1.36M ﹤0.01% 4315
2024
Q4
$49.1K Sell
33,857
-135,546
-80% -$225K ﹤0.01% 5597
2024
Q3
$312K Sell
169,403
-264,352
-61% -$329K ﹤0.01% 5172
2024
Q2
$434K Buy
433,755
+239,988
+124% +$351K ﹤0.01% 4676
2024
Q1
$384K Sell
193,767
-300,325
-61% -$519K ﹤0.01% 4983
2023
Q4
$771K Buy
494,092
+187,469
+61% +$324K ﹤0.01% 4347
2023
Q3
$604K Buy
306,623
+143,157
+88% +$354K ﹤0.01% 4540
2023
Q2
$520K Sell
163,466
-814,937
-83% -$2.56M ﹤0.01% 4510
2023
Q1
$3.2M Buy
978,403
+896,456
+1,094% +$3.52M ﹤0.01% 2997
2022
Q4
$412K Buy
81,947
+18,760
+30% +$74.8K ﹤0.01% 4877
2022
Q3
$144K Buy
63,187
+35,326
+127% +$97.8K ﹤0.01% 5826
2022
Q2
$74K Sell
27,861
-10,684
-28% -$23.2K ﹤0.01% 6040
2022
Q1
$53K Buy
38,545
+27,388
+245% +$56.6K ﹤0.01% 6373
2021
Q4
$35K Buy
+11,157
New +$37K ﹤0.01% 6540

Other funds holding CMPX

Israel Englander's CMPX Position: Q2 2026 in Review

Israel Englander increased its Compass Therapeutics (CMPX) stake by 457% in Q2 2026, buying an estimated $11.4M and bringing the position to 4,713,247 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2248.

Israel Englander first reported a position in CMPX in Q4 2021 and has held it in 19 quarters since. The position peaked at $16.7M in Q4 2025. 214 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Israel Englander held 4,713,247 shares of Compass Therapeutics worth $10.3M as of Q2 2026.
  • Israel Englander bought 3,867,027 Compass Therapeutics shares in Q2 2026, an estimated $11.4M.
  • Compass Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2248 holding.
  • Israel Englander first reported a position in Compass Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Israel Englander's Compass Therapeutics position peaked at $16.7M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.